argenx SE (ARGX) Price Target Analysis
Updated Jul 2, 2026
Analyst Rating: Buy
Based on 36 analysts19.9% Below Target
ARGX trades 19.9% below Wall Street's consensus target of $1103.00.
Current Price$919.94
Average Target$1103.00
Target
Current
Low$890.00
Median$1135.00
High$1291.00
Analyst Target Range
Forward P/E34.8x
(Growth Premium)
PEG Ratio—
Implied Growth+21.1%
(Moderate)
Analyst Spread36.4%
(Moderate)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes ARGX achieves its forward estimates and maintains a stable P/E multiple of 34.8x. This scenario reflects the blended consensus of 36 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
ARGX Price Target Analysis
Updated July 8, 2026As of July 8, 2026, argenx SE (ARGX) has a Wall Street consensus price target of $1103.00, based on estimates from 36 covering analysts. With the stock currently trading at $919.94, this represents a potential upside of +19.9%. The company has a market capitalization of $56.93B.
Analyst price targets range from a low of $890.00 to a high of $1291.00, representing a 36% spread in expectations. The median target of $1135.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 31 analysts rating the stock as a Buy or Strong Buy,5 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ARGX trades at a trailing P/E of 46.9x and forward P/E of 34.8x. Analysts expect EPS to grow +21.1% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $1241.05, with bear and bull scenarios of $781.86 and $1635.21 respectively. Model confidence stands at 61/100, reflecting moderate uncertainty in projections.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+44.4%
Industry Consensus
Avg Forward P/E
27.8x
(Growth Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 RAREUltragenyx Pharmaceutical Inc. | $3.5B | $35.87 | $47.11 | +31.3% | Buy | — | 33 |
 ALNYAlnylam Pharmaceuticals, Inc. | $42.9B | $321.59 | $450.64 | +40.1% | Buy | 43.2x | 52 |
 SRPTSarepta Therapeutics, Inc. | $2.1B | $19.79 | $25.14 | +27.0% | Buy | 5.6x | 54 |
 BMRNBioMarin Pharmaceutical Inc. | $11.6B | $60.35 | $89.21 | +47.8% | Buy | 12.2x | 41 |
 IONSIonis Pharmaceuticals, Inc. | $14.3B | $86.33 | $106.50 | +23.4% | Buy | — | 32 |
 ACADACADIA Pharmaceuticals Inc. | $4.5B | $26.20 | $34.38 | +31.2% | Buy | 68.9x | 37 |
 IMVTImmunovant, Inc. | $8.2B | $40.09 | $45.00 | +12.2% | Buy | — | 23 |
 ARDXArdelyx, Inc. | $1.3B | $5.38 | $17.00 | +216.0% | Buy | — | 16 |
 VRTXVertex Pharmaceuticals Incorporated | $132.8B | $522.25 | $556.00 | +6.5% | Buy | 27.1x | 56 |
 HALOHalozyme Therapeutics, Inc. | $9.7B | $81.57 | $88.25 | +8.2% | Buy | 10.1x | 27 |
ARGX — Frequently Asked Questions
Quick answers to the most common questions about buying ARGX stock.
What is the ARGX stock price target for 2026?
argenx SE (ARGX) has a consensus 12-month price target of $1103, implying 19.9% upside from $919.94. The 36 analysts covering ARGX see moderate appreciation potential.
Is ARGX a buy, sell, or hold?
ARGX has a consensus rating of "Buy" based on 36 Wall Street analysts. The rating breakdown is predominantly bullish, with 31 Buy/Strong Buy ratings. The consensus 12-month price target of $1103 implies 19.9% upside from current levels.
Is ARGX stock overvalued or undervalued?
ARGX trades at a forward P/E of 34.8074x, representing a moderate valuation. With analysts targeting $1103 (19.9% implied move), the stock appears reasonably valued with upside.
How high can ARGX stock go?
The most bullish Wall Street analyst has a price target of $1291 for ARGX, while the most conservative target is $890. The consensus of $1103 represents the median expectation. Our quantitative valuation model projects a bull case target of $1635 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover ARGX stock?
ARGX is heavily covered by Wall Street, with 36 analysts providing price targets and ratings. Of these, 1 have Strong Buy ratings, 30 have Buy ratings, 5 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the ARGX stock forecast?
The 12-month ARGX stock forecast based on 36 Wall Street analysts shows a consensus price target of $1103, with estimates ranging from $890 (bear case) to $1291 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $1241, with bear/bull scenarios of $782/$1635.
What is ARGX's fair value based on fundamentals?
Our quantitative valuation model calculates ARGX's fair value at $1241 (base case), with a bear case of $782 and bull case of $1635. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 61/100.
What is ARGX's forward P/E ratio?
ARGX trades at a forward P/E ratio of 34.8x based on next-twelve-months earnings estimates compared to a trailing P/E of 46.9x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy ARGX stock?
Wall Street analysts are optimistic on ARGX, with a "Buy" consensus rating and $1103 price target (19.9% upside). 31 of 36 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do ARGX price targets vary so much?
ARGX analyst price targets range from $890 to $1291, a 36% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $1103 consensus represents the middle ground. Our model's $782-$1635 range provides an independent fundamental perspective.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare